XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 14,110 $ 223,068 $ (5,546,458) $ (5,309,280)
Beginning balance, shares at Dec. 31, 2019 14,110,004      
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan $ 5 4,994 4,999
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares 4,703      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 39,344 39,344
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 9,750 9,750
Net loss (5,548,873) (5,548,873)
Ending balance, value at Sep. 30, 2020 $ 14,115 277,156 (11,095,331) (10,804,060)
Ending balance, shares at Sep. 30, 2020 14,114,707      
Beginning balance, value at Jun. 30, 2020 $ 14,115 260,791 (9,073,654) (8,798,748)
Beginning balance, shares at Jun. 30, 2020 14,114,707      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 13,114 13,114
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 3,251 3,251
Net loss (2,021,677) (2,021,677)
Ending balance, value at Sep. 30, 2020 $ 14,115 277,156 (11,095,331) (10,804,060)
Ending balance, shares at Sep. 30, 2020 14,114,707      
Beginning balance, value at Dec. 31, 2020 $ 14,115 293,521 (13,825,975) $ (13,518,339)
Beginning balance, shares at Dec. 31, 2020 14,114,707      
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares      
Ending balance, value at Jun. 30, 2021 $ 14,115 3,677,858 (23,641,749) $ (19,949,776)
Ending balance, shares at Jun. 30, 2021 14,114,707      
Beginning balance, value at Dec. 31, 2020 $ 14,115 293,521 (13,825,975) (13,518,339)
Beginning balance, shares at Dec. 31, 2020 14,114,707      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 6,045,455 6,045,455
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 111,084 111,084
Net loss (16,772,393) (16,772,393)
Ending balance, value at Sep. 30, 2021 $ 14,115 6,450,060 (30,598,368) (24,134,193)
Ending balance, shares at Sep. 30, 2021 14,114,707      
Beginning balance, value at Jun. 30, 2021 $ 14,115 3,677,858 (23,641,749) (19,949,776)
Beginning balance, shares at Jun. 30, 2021 14,114,707      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 2,716,747 2,716,747
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 55,455 55,455
Net loss (6,956,619) (6,956,619)
Ending balance, value at Sep. 30, 2021 $ 14,115 $ 6,450,060 $ (30,598,368) $ (24,134,193)
Ending balance, shares at Sep. 30, 2021 14,114,707